Skip to main content

Table 5 Correlation between disease characteristics and CT-based therapeutic response in the study population

From: Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma

 Objective response by RECISTTest value*P valueSig.
CMRPMRSMDPMD
No. =  8No. = 18No. = 3No. = 4
Pathology
NHL3 (37.5%)9 (50.0%)0 (0.0%)3(75.0%)5.4350.489NS
HL5 (62.5%)8 (44.4%)3 (100.0%)1 (25.0%)
GALT0 (0.0%)1 (5.6%)0 (0.0%)0 (0.0%)
Location
NA1 (12.5%)2 (11.1%)0 (0.0%)1 (25.0%)10.5300.104NS
Supra6 (75.0%)5 (27.8%)3 (100.0%)1 (25.0%)
Supra & infra1 (12.5%)11 (61.1%)0 (0.0%)2 (50.0%)
Stage
I1 (12.5%)1 (5.6%)0 (0.0%)0 (0.0%)26.2030.095NS
IE1 (12.5%)0 (0.0%)0 (0.0%)0 (0.0%)
II4 (50.0%)4 (22.2%)3 (100.0%)0 (0.0%)
IIE1 (12.5%)0 (0.0%)0 (0.0%)0 (0.0%)
III0 (0.0%)3 (16.7%)0 (0.0%)2 (50.0%)
IIIS1 (12.5%)6 (33.3%)0 (0.0%)0 (0.0%)
IV0 (0.0%)4 (22.2%)0 (0.0%)2 (50.0%)
New lesion
Absent8 (100.0%)18 (100%)3 (100.0%)0 (0.0%)33.0000.000HS
Present0 (0.0%)0 (0.0%)0 (0.0%)4 (100.0%)
  1. P value > 0.05 Non significant (NS), P value < 0.05 Significant (S), P value < 0.01 Highly significant (HS)
  2. *Chi-square test